Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1111/jcmm.15674 http://scihub22266oqcxt.onion/10.1111/jcmm.15674 32713161!7521316!32713161     free     free     free Deprecated: Implicit conversion from float 213.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 213.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 213.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 213.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 213.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       J+Cell+Mol+Med 2020 ; 24 (18): 10274-10278 Nephropedia Template TP {{tp|p=32713161|t=2020. The potential effects of DPP-4 inhibitors on cardiovascular system in COVID-19 patients |pdf=|usr=}}{{32713161}} gab.com Text The potential effects of DPP-4 inhibitors on cardiovascular system in COVID-19 patients JO: J Cell Mol Med http://www.kidney.de/pget.php?&tw=1&pmid=32713161 #FOAvip With the outbreak of a new coronavirus, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the public healthcare systems are facing great challenges. Coronavirus disease 2019 (COVID-19) could develop into severe pneumonia, acute respiratory distress syndrome and multi-organ failure. Remarkably, in addition to the respiratory symptoms, some COVID-19 patients also suffer from cardiovascular injuries. Dipeptidyl peptidase-4 (DPP-4) is a ubiquitous glycoprotein which could act both as a cell membrane-bound protein and a soluble enzymatic protein after cleavage and release into the circulation. Despite angiotensin-converting enzyme 2 (ACE2), the recently recognized receptor of SARS-CoV and SARS-CoV-2, which facilitated their entries into the host, DPP-4 has been identified as the receptor of middle east respiratory syndrome coronavirus (MERS-CoV). In the current review, we discussed the potential roles of DPP-4 in COVID-19 and the possible effects of DPP-4 inhibitors on cardiovascular system in patients with COVID-19. Twit Text FOAVip The potential effects of DPP-4 inhibitors on cardiovascular system in COVID-19 patients ????J Cell Mol Med http://www.kidney.de/pget.php?&tw=1&pmid=32713161 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=32713161 #FOAvip English Wikipedia <ref>{{Cite pmid|32713161}}</ref> The potential effects of DPP-4 inhibitors on cardiovascular system in COVID-19 patients #MMPMID32713161 Du H; Wang DW; Chen C J Cell Mol Med 2020[Sep]; 24 (18): 10274-10278 PMID32713161show ga With the outbreak of a new coronavirus, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the public healthcare systems are facing great challenges. Coronavirus disease 2019 (COVID-19) could develop into severe pneumonia, acute respiratory distress syndrome and multi-organ failure. Remarkably, in addition to the respiratory symptoms, some COVID-19 patients also suffer from cardiovascular injuries. Dipeptidyl peptidase-4 (DPP-4) is a ubiquitous glycoprotein which could act both as a cell membrane-bound protein and a soluble enzymatic protein after cleavage and release into the circulation. Despite angiotensin-converting enzyme 2 (ACE2), the recently recognized receptor of SARS-CoV and SARS-CoV-2, which facilitated their entries into the host, DPP-4 has been identified as the receptor of middle east respiratory syndrome coronavirus (MERS-CoV). In the current review, we discussed the potential roles of DPP-4 in COVID-19 and the possible effects of DPP-4 inhibitors on cardiovascular system in patients with COVID-19. |*COVID-19 Drug Treatment[MESH] |Cardiovascular Diseases/*enzymology/virology[MESH] |Dipeptidyl Peptidase 4/*metabolism[MESH] |Dipeptidyl-Peptidase IV Inhibitors/*pharmacology[MESH] |Host-Pathogen Interactions[MESH] |Humans[MESH] |SARS-CoV-2/physiology[MESH]The potential effects of DPP-4 inhibitors on cardiovascular system in (epmc).pdf DeepDyve Pubget Overpricing